<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723021</url>
  </required_header>
  <id_info>
    <org_study_id>B0041002</org_study_id>
    <nct_id>NCT00723021</nct_id>
  </id_info>
  <brief_title>PF-04191834 Single Dose Bronchodilatory Study In Asthma.</brief_title>
  <official_title>A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in
      patients with asthma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline, 12 hours (hrs) post-dose</time_frame>
    <description>The FEV1 is the maximal volume of air that can be forcefully exhaled in one second</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline, 24 hours (hrs) post-dose</time_frame>
    <description>The FEV1 is the maximal volume of air that can be forcefully exhaled in one second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline, 12 hours (hrs) post-dose</time_frame>
    <description>The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline,24 hours (hrs) post-dose</time_frame>
    <description>The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)</measure>
    <time_frame>Baseline, 12 hours (hrs) post-dose</time_frame>
    <description>The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)</measure>
    <time_frame>Baseline, 24 hours (hrs) post-dose</time_frame>
    <description>The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]</measure>
    <time_frame>14 and 24 hours following dosing in each period.</time_frame>
    <description>AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>PF-04191834 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04191834 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04191834 2000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>zileuton</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04191834</intervention_name>
    <description>30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.</description>
    <arm_group_label>PF-04191834 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04191834</intervention_name>
    <description>100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.</description>
    <arm_group_label>PF-04191834 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04191834</intervention_name>
    <description>2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose</description>
    <arm_group_label>PF-04191834 2000mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zileuton</intervention_name>
    <description>1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.</description>
    <arm_group_label>zileuton</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 x placebo tablets + placebo oral dispersion, single dose.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent mild/moderate asthma for at least 6 months.

          -  Reduced lung function

          -  Reversible airway obstruction

        Exclusion Criteria:

          -  Pregnant/nursing females.

          -  Liver function tests greater than upper limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0041002&amp;StudyName=PF-04191834%20Single%20Dose%20Bronchodilatory%20Study%20In%20Asthma.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <results_first_submitted>December 27, 2012</results_first_submitted>
  <results_first_submitted_qc>December 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2013</results_first_posted>
  <disposition_first_submitted>March 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 28, 2011</disposition_first_posted>
  <last_update_submitted>December 27, 2012</last_update_submitted>
  <last_update_submitted_qc>December 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zileuton</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence 1</title>
          <description>Placebo/Zileuton CR 1200 mg/PF-04191834 30 mg/PF-04191834 2000 mg/PF-04191834 100 mg</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence 2</title>
          <description>PF-04191834 100 mg/PF-04191834 30 mg/PF-04191834 2000 mg/Placebo/Zileuton CR 1200 mg</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence 3</title>
          <description>PF-04191834 2000 mg/PF-04191834 100 mg/Zileuton CR 1200 mg/PF-04191834 30 mg/Placebo</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence 4</title>
          <description>PF-04191834 30 mg/Placebo/PF-04191834 100 mg/Zileuton CR 1200 mg/PF-04191834 2000 mg</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence 5</title>
          <description>Zileuton CR 1200 mg/PF-04191834 2000 mg/Placebo/PF-04191834 100 mg/PF-04191834 30 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants receiving any of the 5 treatments (PF-04191834 30 mg, PF-04191834 100 mg, PF-04191834 2000 mg, Zileuton CR 1200 mg and Placebo) in a randomized fashion first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The FEV1 is the maximal volume of air that can be forcefully exhaled in one second</description>
        <time_frame>Baseline, 12 hours (hrs) post-dose</time_frame>
        <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O4">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
          <group group_id="O5">
            <title>Zileuton CR 1200 mg</title>
            <description>Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The FEV1 is the maximal volume of air that can be forcefully exhaled in one second</description>
          <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.624" spread="0.3939"/>
                    <measurement group_id="O2" value="2.626" spread="0.3860"/>
                    <measurement group_id="O3" value="2.585" spread="0.5200"/>
                    <measurement group_id="O4" value="2.579" spread="0.4131"/>
                    <measurement group_id="O5" value="2.609" spread="0.4502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 Hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.3098"/>
                    <measurement group_id="O2" value="0.164" spread="0.1859"/>
                    <measurement group_id="O3" value="0.152" spread="0.2072"/>
                    <measurement group_id="O4" value="0.265" spread="0.3047"/>
                    <measurement group_id="O5" value="0.131" spread="0.1566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The FEV1 is the maximal volume of air that can be forcefully exhaled in one second</description>
        <time_frame>Baseline, 24 hours (hrs) post-dose</time_frame>
        <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O4">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
          <group group_id="O5">
            <title>Zileuton CR 1200 mg</title>
            <description>Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The FEV1 is the maximal volume of air that can be forcefully exhaled in one second</description>
          <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.624" spread="0.3939"/>
                    <measurement group_id="O2" value="2.626" spread="0.3860"/>
                    <measurement group_id="O3" value="2.585" spread="0.5200"/>
                    <measurement group_id="O4" value="2.579" spread="0.4131"/>
                    <measurement group_id="O5" value="2.609" spread="0.4502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 24 Hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" spread="0.2553"/>
                    <measurement group_id="O2" value="0.014" spread="0.2318"/>
                    <measurement group_id="O3" value="0.103" spread="0.2616"/>
                    <measurement group_id="O4" value="0.162" spread="0.1559"/>
                    <measurement group_id="O5" value="0.151" spread="0.1338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
        <description>The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible</description>
        <time_frame>Baseline, 12 hours (hrs) post-dose</time_frame>
        <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each subject received 2 x placebo tablets ( for zileuton 600 mg tablets) + placebo oral dispersion (for PF-04191834), single dose</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 30 mg</title>
            <description>Each subject received PF-04191834 30 mg, single dose, oral dispersion + 2 x placebo tablets</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 100 mg</title>
            <description>Each subject received PF-04191834 100 mg, single dose, oral disersion + 2 x placebo tablets, single dose</description>
          </group>
          <group group_id="O4">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
          <group group_id="O5">
            <title>Zileuton CR 1200 mg</title>
            <description>Each subject received zileuton CR 1200 mg, 2x600 mg tablets, single dose + placebo oral dispersion, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
          <description>The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible</description>
          <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.852" spread="0.8865"/>
                    <measurement group_id="O2" value="3.891" spread="0.8625"/>
                    <measurement group_id="O3" value="3.720" spread="0.8930"/>
                    <measurement group_id="O4" value="3.792" spread="0.9100"/>
                    <measurement group_id="O5" value="3.821" spread="0.9914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 Hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.3306"/>
                    <measurement group_id="O2" value="0.284" spread="0.4150"/>
                    <measurement group_id="O3" value="0.210" spread="0.4792"/>
                    <measurement group_id="O4" value="0.266" spread="0.3184"/>
                    <measurement group_id="O5" value="0.140" spread="0.2750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
        <description>The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible</description>
        <time_frame>Baseline,24 hours (hrs) post-dose</time_frame>
        <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O4">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
          <group group_id="O5">
            <title>Zileuton CR 1200 mg</title>
            <description>Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC)</title>
          <description>The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible</description>
          <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.852" spread="0.8865"/>
                    <measurement group_id="O2" value="3.891" spread="0.8625"/>
                    <measurement group_id="O3" value="3.720" spread="0.8930"/>
                    <measurement group_id="O4" value="3.792" spread="0.9100"/>
                    <measurement group_id="O5" value="3.821" spread="0.9914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 24 Hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.162" spread="0.2322"/>
                    <measurement group_id="O2" value="0.051" spread="0.2839"/>
                    <measurement group_id="O3" value="0.229" spread="0.3657"/>
                    <measurement group_id="O4" value="0.171" spread="0.2070"/>
                    <measurement group_id="O5" value="0.219" spread="0.2977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)</title>
        <description>The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity</description>
        <time_frame>Baseline, 12 hours (hrs) post-dose</time_frame>
        <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each subject received 2 x placebo tablets ( for zileuton 600 mg tablets) + placebo oral dispersion (for PF-04191834), single dose</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 30 mg</title>
            <description>Each subject received PF-04191834 30 mg, single dose, oral dispersion + 2 x placebo tablets</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 100 mg</title>
            <description>Each subject received PF-04191834 100 mg, single dose, oral disersion + 2 x placebo tablets, single dose</description>
          </group>
          <group group_id="O4">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
          <group group_id="O5">
            <title>Zileuton CR 1200 mg</title>
            <description>Each subject received zileuton CR 1200 mg, 2x600 mg tablets, single dose + placebo oral dispersion, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)</title>
          <description>The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity</description>
          <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
          <units>L/Sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.951" spread="0.4550"/>
                    <measurement group_id="O2" value="1.901" spread="0.4228"/>
                    <measurement group_id="O3" value="1.807" spread="0.4452"/>
                    <measurement group_id="O4" value="1.915" spread="0.4488"/>
                    <measurement group_id="O5" value="1.959" spread="0.4378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 Hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.3556"/>
                    <measurement group_id="O2" value="0.340" spread="0.4238"/>
                    <measurement group_id="O3" value="0.269" spread="0.3033"/>
                    <measurement group_id="O4" value="0.297" spread="0.3871"/>
                    <measurement group_id="O5" value="0.187" spread="0.3757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)</title>
        <description>The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity</description>
        <time_frame>Baseline, 24 hours (hrs) post-dose</time_frame>
        <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O4">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
          <group group_id="O5">
            <title>Zileuton CR 1200 mg</title>
            <description>Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)</title>
          <description>The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity</description>
          <population>All enrolled participants treated who had at least 1 concentration in at least 1 treatment period</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.951" spread="0.4550"/>
                    <measurement group_id="O2" value="1.901" spread="0.4228"/>
                    <measurement group_id="O3" value="1.807" spread="0.4452"/>
                    <measurement group_id="O4" value="1.915" spread="0.4488"/>
                    <measurement group_id="O5" value="1.959" spread="0.4378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 24 Hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" spread="0.3049"/>
                    <measurement group_id="O2" value="0.038" spread="0.1952"/>
                    <measurement group_id="O3" value="0.196" spread="0.2169"/>
                    <measurement group_id="O4" value="0.151" spread="0.2030"/>
                    <measurement group_id="O5" value="0.208" spread="0.3483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
        <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
        <population>All enrolled subjects treated who have at least one of the PK parameters of interest in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
          <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
          <population>All enrolled subjects treated who have at least one of the PK parameters of interest in at least one treatment period.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1979" spread="482"/>
                    <measurement group_id="O2" value="5547" spread="1388"/>
                    <measurement group_id="O3" value="29990" spread="8812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
        <population>All enrolled subjects treated who have at least one of the PK parameters of interest in at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>All enrolled subjects treated who have at least one of the PK parameters of interest in at least one treatment period.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="29"/>
                    <measurement group_id="O2" value="426" spread="118"/>
                    <measurement group_id="O3" value="2146" spread="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <units>hrs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="14"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O3" value="10" lower_limit="4" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.</time_frame>
        <population>Since the PK sample collection only occurred until 24 hours and the approximate t1/2 at all doses appeared to be &gt;10 hours, t1/2 and area under the plasma concentration versus time curve until infinity (AUCinf) are not reported at any dose level.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>Since the PK sample collection only occurred until 24 hours and the approximate t1/2 at all doses appeared to be &gt;10 hours, t1/2 and area under the plasma concentration versus time curve until infinity (AUCinf) are not reported at any dose level.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]</title>
        <description>AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).</description>
        <time_frame>14 and 24 hours following dosing in each period.</time_frame>
        <population>Since the PK sample collection only occurred until 24 hours and the approximate t1/2 at all doses appeared to be &gt;10 hours, t1/2 and area under the plasma concentration versus time curve until infinity (AUCinf) are not reported at any dose level.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04191834 30 mg</title>
            <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
          </group>
          <group group_id="O2">
            <title>PF-04191834 100 mg</title>
            <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
          </group>
          <group group_id="O3">
            <title>PF-04191834 2000 mg</title>
            <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]</title>
          <description>AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).</description>
          <population>Since the PK sample collection only occurred until 24 hours and the approximate t1/2 at all doses appeared to be &gt;10 hours, t1/2 and area under the plasma concentration versus time curve until infinity (AUCinf) are not reported at any dose level.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period</description>
        </group>
        <group group_id="E2">
          <title>PF-04191834 30 mg</title>
          <description>Participants received a single oral dose of PF-04191834 30 mg in any treatment period</description>
        </group>
        <group group_id="E3">
          <title>PF-04191834 100 mg</title>
          <description>Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period</description>
        </group>
        <group group_id="E4">
          <title>PF-04191834 2000 mg</title>
          <description>Participants received a single oral dose of PF-04191834 2000 mg in any treatment period</description>
        </group>
        <group group_id="E5">
          <title>Zileuton CR 1200 mg</title>
          <description>Paticipants received single oral dose of zileuton CR1200 mg (2 x 600 mg tablets) in any treatment period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

